- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01135095
Low Dose One-Day Tc99m Protocol With a High-Efficiency Cardiac Dedicated Gamma Camera For Detection of Coronary Disease
Validation of a Low-Dose One-Day TC99m Protocol With a High-Efficiency Cardiac Dedicated Gamma Camera for Detection of Coronary Artery Disease
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 00000
- Cedars-Sinai Medical Center
-
-
Oregon
-
Springfield, Oregon, United States, 00000
- Oregon Heart and Vascular Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is referred to myocardial perfusion D-SPECT for clinical indications.
- Written informed consent is obtained by a study investigator.
Exclusion Criteria:
- Patient is diagnosed as having uncontrolled congestive cardiac failure or cardiogenic shock.
- Patient is diagnosed as having uncontrolled hypertension with resting blood pressure > 220 mm Hg systolic or 110 mm Hg diastolic.
- Patient pregnancy (known or suspected).
- Lack of written informed consent
- Prisoner status
- Minors under the age of 18 as coronary artery disease is generally an adult disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: low-dose imaging
low dose versus standard dose imaging
|
The study is designed to assess the validity of a low dose (~5mSv) Tc99m one day protocol using D-SPECT standard protocol as the comparators. D-SPECT cardiac scanner the D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large photomultiplier tubes. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Summed Rest Score (SRS) Using American Heart Association 17 Segment Polar Map Model
Time Frame: 1 day
|
SRS is used to quantify presence/severity of SPECT rest myocardial perfusion defects, as assessed by visual analysis using American Heart Association (AHA) 17 segment polar map model; each segment correlates to a myocardial location.
Perfusion abnormalities can be determined in relation to myocardial segment/s affected by ischemia and the perfusion defect severity scored using 0 - 4 scale for each segment (0, normal uptake; 1, mildly reduced uptake; 2, moderately reduced uptake; 3, severely reduced uptake; and 4, no uptake).
SRS is calculated by summing individual scores from each of 17 segments to give an overall score between 0 and 68; a score of 0 indicates normal outcome and scores > 0 indicate increasingly worse outcomes as the score increases.
For each patient, SRS will be compared between standard-low-dose (SLD) imaging from a conventional A-SPECT camera and ultra-low-dose (ULD) imaging from a high-efficiency D-SPECT camera, both acquired on the same day.
|
1 day
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Andrew Einstein, MD,PHD, Columbia University Medical Center, Department of Medicine, Division of Cardiology
- Principal Investigator: Dan Berman, MD, Cedars-Sinai Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SD-DSPECT002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chest Pain
-
Clinical Locomotion ScienceOdense University Hospital; University of Southern Denmark; The County of Funen... and other collaboratorsCompletedUndiagnosed Chest Pain | Musculoskeletal Chest Pain | Non-cardiac Chest PainDenmark
-
Academisch Medisch Centrum - Universiteit van Amsterdam...TerminatedFunctional Chest PainNetherlands
-
Ataturk UniversityCompletedPain, Acute | Pain, ChestTurkey
-
Queen's UniversityCompletedChest Pain Atypical SyndromeCanada
-
Cairo UniversityActive, not recruitingNonspecific Cardiac Chest PainEgypt
-
Universiti Sains MalaysiaCompletedNon Cardiac Chest PainMalaysia
-
Milton S. Hershey Medical CenterCompletedNoncardiac Chest Pain (NCCP)United States
-
Fayoum University HospitalCompleted
-
University of Texas Southwestern Medical CenterCompletedAcute Chest PainUnited States
-
Massachusetts General HospitalBracco Diagnostics, IncCompletedChest Pain SyndromeUnited States
Clinical Trials on low-dose imaging
-
McMaster UniversityMcMaster Surgical AssociatesCompleted
-
Yale UniversityAgency for Healthcare Research and Quality (AHRQ)Completed
-
Shanghai Chest HospitalRecruiting
-
Philips Clinical & Medical Affairs GlobalCompletedCardiovascular DiseaseNetherlands
-
Shanghai Changzheng HospitalUnknownCardiovascular Disease | Lung Neoplasms | Chronic Obstructive Pulmonary Disease | Mass ScreeningChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico